Obesity has reached epidemic proportions in industrialized countries, where it has become a leading cause of morbidity and premature mortality. Moreover, the unprecedented prevalence of this epidemic among children will likely exacerbate its future course and intensify the frequency of comorbid disorders such as diabetes, atherosclerosis and heart disease. Although lifestyle changes are the first line of treatment for obesity, when this option fails drug therapy becomes a necessity. We have recently discovered that a natural lipid compound produced by cells in the upper intestine, called oleoylethanolamide (OEA), inhibits feeding, reduces body weight and lowers serum lipids in obese rodents. OEA causes these effects by binding with nanomolar affinity to the nuclear receptor PPAR-alpha (peroxisome proliferator-activated receptor type-alpha). However, the rapid hydrolytic degradation of this natural compound shortens its biological actions and limits its potential usefulness in anti-obesity therapy. Therefore, the goal of the present proposal is to develop hydrolysis-resistant analogs of OEA with prolonged duration of action. Lead compounds identified in these Phase I studies will undergo further pharmacological, pharmacokinetic and toxicological characterization in subsequent Phase II investigations, with the ultimate objective of developing these agents into a new class of anti-obesity drugs. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41DK070347-01
Application #
6880388
Study Section
Special Emphasis Panel (ZRG1-EMNR-E (10))
Program Officer
Densmore, Christine L
Project Start
2005-09-20
Project End
2006-08-31
Budget Start
2005-09-20
Budget End
2006-08-31
Support Year
1
Fiscal Year
2005
Total Cost
$100,000
Indirect Cost
Name
Kadmus Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Irvine
State
CA
Country
United States
Zip Code
92612
Russo, Roberto; LoVerme, Jesse; La Rana, Giovanna et al. (2007) Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur J Pharmacol 566:117-9
Astarita, Giuseppe; Di Giacomo, Barbara; Gaetani, Silvana et al. (2006) Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther 318:563-70
Astarita, Giuseppe; Rourke, Bryan C; Andersen, Johnnie B et al. (2006) Postprandial increase of oleoylethanolamide mobilization in small intestine of the Burmese python (Python molurus). Am J Physiol Regul Integr Comp Physiol 290:R1407-12